Literature DB >> 24240504

Volumetric evaluation of an alternative bladder point in brachytherapy for locally advanced cervical cancer.

R Mazeron1, J Gilmore, J Champoudry, I Dumas, J Helou, P Maroun, F Martinetti, A Gerbaulet, C Haie-Meder.   

Abstract

PURPOSE: To evaluate an alternative dose point, so-called ALG (for Alain Gerbaulet), for the bladder in comparison to the International Commission on Radiation Units and Measurements (ICRU) point and D2cm(3) (minimal dose to maximally exposed 2 cm(3)) in a large cohort of patients with locally advanced cervical cancer treated with external beam radiotherapy followed by image-guided pulsed dose rate brachytherapy. METHODS AND MATERIALS: For each patient, the ALG point was constructed 1.5 cm above the ICRU bladder, parallel to the tandem (coronal and sagittal planes). The dosimetric data from 162 patients were reviewed.
RESULTS: Average doses to ALG and bladder points were 19.40 Gy ± 7.93 and 17.14 ± 8.70, respectively (p=0.01). The 2 cm(3) bladder dose averaged 24.40 ± 6.77 Gy. Ratios between D2cm(3) and dose points were 1.37 ± 0.46 and 1.68 ± 0.74 (p<0.001) for ALG and ICRU points, respectively. Both dose points appeared correlated with D2cm(3) (p<0.001) with coefficients of determination (R(2)) of 0.331 and 0.399 respectively. The estimated dose to the ICRU point of the rectum was 12.77 ± 4.21 and 15.76 ± 5.94 for D2cm(3) (p<0.0001). Both values were significantly correlated (p<0.0001, R(2) = 0.485).
CONCLUSION: The ALG point underestimates the D2cm(3), but its mean on a large cohort is closer to D2cm(3) than the dose to ICRU point. However, it shows great variability between cases and the weak strength of its correlation to D2cm(3) indicates that it is not a good surrogate for individual volumetric evaluation of the dose D2cm(3).

Entities:  

Mesh:

Year:  2013        PMID: 24240504     DOI: 10.1007/s00066-013-0463-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  22 in total

1.  Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy.

Authors:  Mihai Levitchi; Claire Charra-Brunaud; Philippe Quetin; Christine Haie-Meder; Christine Kerr; Bernard Castelain; Martine Delannes; Laurence Thomas; Emmanuel Desandes; Didier Peiffert
Journal:  Radiother Oncol       Date:  2012-05-24       Impact factor: 6.280

2.  Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.

Authors:  Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits
Journal:  Radiother Oncol       Date:  2006-01-05       Impact factor: 6.280

3.  The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosimetric results.

Authors:  Christian Kirisits; Stefan Lang; Johannes Dimopoulos; Daniel Berger; Dietmar Georg; Richard Pötter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

4.  Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point.

Authors:  Natascha Wachter-Gerstner; Stefan Wachter; Evi Reinstadler; Claudia Fellner; Tomas H Knocke; Andre Wambersie; Richard Pötter
Journal:  Radiother Oncol       Date:  2003-09       Impact factor: 6.280

5.  Feasibility of transrectal ultrasonography for assessment of cervical cancer.

Authors:  M P Schmid; R Pötter; P Brader; A Kratochwil; G Goldner; K Kirchheiner; A Sturdza; C Kirisits
Journal:  Strahlenther Onkol       Date:  2012-12-21       Impact factor: 3.621

6.  Maximum and mean bladder dose defined from ultrasonography. Comparison with the ICRU reference in gynaecological brachytherapy.

Authors:  I Barillot; J C Horiot; P Maingon; M C Bone-Lepinoy; D Vaillant; S Feutray
Journal:  Radiother Oncol       Date:  1994-03       Impact factor: 6.280

7.  Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer.

Authors:  P Georg; A Boni; A Ghabuous; G Goldner; M P Schmid; D Georg; R Pötter; W Dörr
Journal:  Strahlenther Onkol       Date:  2013-05-25       Impact factor: 3.621

8.  Analysis of complications of cervix carcinoma treated by radiotherapy using the Franco-Italian glossary.

Authors:  G Sinistrero; P Sismondi; A Rumore; P Zola
Journal:  Radiother Oncol       Date:  1993-03       Impact factor: 6.280

9.  Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer.

Authors:  Renaud Mazeron; Jennifer Gilmore; Isabelle Dumas; Jérôme Champoudry; Jennifer Goulart; Ben Vanneste; Anne Tailleur; Philippe Morice; Christine Haie-Meder
Journal:  Oncologist       Date:  2013-04-08

10.  Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy.

Authors:  Petra Georg; Christian Kirisits; Gregor Goldner; Wolfgang Dörr; Johann Hammer; Regina Pötzi; Daniel Berger; Johannes Dimopoulos; Dietmar Georg; Richard Pötter
Journal:  Radiother Oncol       Date:  2009-02-23       Impact factor: 6.280

View more
  4 in total

1.  Application of organ tolerance dose-constraints in clinical studies in radiation oncology.

Authors:  Wolfgang Dörr; Thomas Herrmann; Michael Baumann
Journal:  Strahlenther Onkol       Date:  2014-03-07       Impact factor: 3.621

2.  Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy.

Authors:  Simone Marnitz; Johanna Schram; Volker Budach; Irina Sackerer; Giuseppe Filiberto Vercellino; Jalid Sehouli; Christhardt Köhler
Journal:  Strahlenther Onkol       Date:  2014-11-21       Impact factor: 3.621

3.  Effect of rectal enemas on rectal dosimetric parameters during high-dose-rate vaginal cuff brachytherapy: A prospective trial.

Authors:  Sebastià Sabater; Ignacio Andrés; Marina Gascon; Angeles Rovirosa; Marimar Sevillano; Roberto Berenguer; Cristina Camacho-Lopez; Manuel Aguayo; Maria Victoria Villas; Meritxell Arenas
Journal:  Strahlenther Onkol       Date:  2016-01-23       Impact factor: 3.621

4.  Target tailoring and proton beam therapy to reduce small bowel dose in cervical cancer radiotherapy : A comparison of benefits.

Authors:  Peter de Boer; Agustinus J A J van de Schoot; Henrike Westerveld; Mark Smit; Marrije R Buist; Arjan Bel; Coen R N Rasch; Lukas J A Stalpers
Journal:  Strahlenther Onkol       Date:  2017-11-03       Impact factor: 3.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.